SCHEMBL21106927

SCHEMBL21106927

CC(=O)NCCCCOCCCCC(C)C

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.52
MAPK1 P28482 1/20 0.52
HIF1A Q16665 1/20 0.52
PAOX Q6QHF9 3/20 0.44
ADRA1A P35348 1/20 0.43
FOLH1 Q04609 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40
MTNR1A P48039 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ZDHHC7 Q9NXF8 1/20 0.38
EPHX2 P34913 2/20 0.37
PLA2G2C Q5R387 1/20 0.37
MAPT P10636 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TSHR P16473 1/20 0.36
RARB P10826 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21106551 0.97 KDM4E (0.53) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL25881434 0.91 KDM4E (0.48) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL4762422 0.89 KDM4E (0.65) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21106575 0.87 MEN1 (0.47) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL21227771 0.87 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL7829295 0.87 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL15981282 0.87 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL20859598 0.87 KDM4E (0.70) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL23560063 0.86 MEN1 (0.50) KDM4EMAPK1HIF1APAOXADRA1A
SCHEMBL22793879 0.86 MEN1 (0.50) KDM4EMAPK1HIF1APAOXADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11779578-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-10-10 US disclosed
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-09-28 US disclosed
US-11746120-B2 Stat degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 US disclosed
US-11707457-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-07-25 US disclosed
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-05-11 US disclosed
WO-2022125804-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-20240025878-A1 MDM2 DEGRADERS AND USES THEREOF MDM2, TP53, MDM4 KDM4E 1073/4885MAPK1 4323/4885HIF1A 1514/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-11746120-B2 Stat degraders and uses thereof STAT4, STAT1, STAT3 KDM4E 414/4885MAPK1 3754/4885HIF1A 3093/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-20230303526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-11779578-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-11707457-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885
US-20230144292-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885MAPK1 2017/4885HIF1A 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.